| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
Cadrofloxacin manufacturers
- Cadrofloxacin
-
- $2500.00
-
2026-05-11
- CAS:153808-85-6
- Purity:
- Supply Ability: 10g
|
| | Cadrofloxacin Basic information |
| Product Name: | Cadrofloxacin | | Synonyms: | Cadrofloxacin;Caderofloxacin;1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-[(3S)-3-methylpiperazin-1-yl]-4-oxo-quinoline-3-carboxylic acid;3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoroMethoxy)-6-fluoro-1,4-dihydro-7-[(3S)-3-Methyl-1-piperazinyl]-4-oxo-;Cadrofloxacin USP/EP/BP | | CAS: | 153808-85-6 | | MF: | C19H20F3N3O4 | | MW: | 411.38 | | EINECS: | | | Product Categories: | | | Mol File: | 153808-85-6.mol |  |
| | Cadrofloxacin Chemical Properties |
| Boiling point | 602.4±55.0 °C(Predicted) | | density | 1.458±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 10 mg/mL (24.31 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 80°C) | | pka | 6.40±0.50(Predicted) | | form | Solid | | color | White to off-white |
| | Cadrofloxacin Usage And Synthesis |
| Uses | Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases[1][2][3]. | | in vivo | Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats[2]. | Animal Model: | Male Sprague-Dawley rats weighing 180-220 g[2] | | Dosage: | 9 mg/kg | | Administration: | I.g. once or twice daily for 14 consecutive days | | Result: | Enhanced the expression of hepatic CYP2E1 mRNA, inducing a 1.6-fold increase compared with that of control rats.
The level of CYP2E1 protein in the hepatic microsomes was significantly higher than control group, 190% of that in control rats.
|
| | References | [1] Biedenbach DJ, et al. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30. DOI:10.1128/AAC.39.10.2325
[2] Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58. DOI:10.1517/13543784.11.2.233 |
| | Cadrofloxacin Preparation Products And Raw materials |
|